Context During the past decade, several urinary biomarker tests (UBTs) for bladder cancer
have been developed and made commercially available. However, none of these is …

Bladder cancer is the most common malignancy of the urinary tract. Cystoscopy represents
the gold standard in the diagnosis of suspicious bladder lesions. However, the procedure is …

Precision medicine has transformed the way urothelial carcinoma is managed. However,
current practices are limited by the availability of tissue samples for genomic profiling and …

Bladder cancer (BC) is characterized by high incidence and recurrence rates together with
genomic instability and elevated mutation degree. Currently, cystoscopy combined with …

Bladder cancer is a common urological cancer with a high recurrence rate that requires long‐
term follow‐up, and early detection positively affects prognosis. To date, the initial diagnosis …

Bladder cancer (BC) is the 10th most frequent cancer in the world. The initial diagnosis and
surveillance of BC require a combination of invasive and non-invasive methods, which are …

The types of urothelial carcinoma (UC) include urothelial bladder cancer and upper tract
urothelial carcinoma. Current diagnostic techniques cannot meet the needs of patients …

The standard treatment paradigm for muscle invasive bladder cancer has been neoadjuvant
cisplatin-based chemotherapy followed by radical cystectomy. However, efforts are ongoing …

Simple Summary Bladder cancer (BC) is a common cancer that causes high morbidity and
mortality among affected patients. As a carcinogen-driven cancer, molecular oncology of BC …

The aim of this review is to analyze and describe the current landscape of bladder cancer
diagnostic and surveillance biomarkers. We researched the literature from 2016 to …